Many non-conformities identified during GMP inspections are not based on isolated incidents, but on recurring deficiencies. Compliance issues in documentation, quality assurance or training can increase regulatory risks and lead to critical deficiencies during an inspection.

Why recurring GMP non-conformities pose a risk

The requirements of Good Manufacturing Practice (GMP) serve to protect patients and ensure consistently high product quality. Nevertheless, GMP inspections repeatedly reveal similar weaknesses in pharmaceutical companies.

Deficiencies often arise not from individual poor decisions, but from inadequately established processes. If risks are not identified in good time or measures are not consistently implemented, minor shortcomings can develop into significant quality problems. Inspectors therefore pay particular attention to whether companies are monitoring and continuously improving their quality processes in a sustainable manner.

Errors in GMP documentation are among the most common findings

Comprehensive GMP documentation forms the basis of every pharmaceutical quality system. Nevertheless, documentation deficiencies are regularly among the most common findings during inspections. These include incomplete entries, missing signatures, changes that cannot be traced, or delayed documentation of work steps. Unclear lines of responsibility can also lead to important information not being recorded correctly.

As documents serve as evidence of the proper execution of processes, inspectors assess such deficiencies particularly critically. Companies should therefore ensure that all staff are familiar with the applicable documentation requirements and apply them consistently.

Weaknesses in training and CAPA processes

Another frequent point of criticism concerns the qualification of staff. Whilst training courses are carried out, their effectiveness is not always adequately verified. Inspectors expect verifiable evidence that staff are able to perform their tasks in accordance with the applicable GMP requirements.

Deficiencies also regularly arise in the area of CAPA. Corrective actions are often defined without sufficiently analysing the root causes of a problem. Without a thorough root cause analysis, there is a risk that the same deficiencies will recur.

An effective quality management system ensures that deviations are systematically investigated and sustainable improvement measures are implemented.

Data integrity and risk management in the inspectors’ focus

In recent years, issues such as data integrity and risk management have become significantly more important. Regulatory authorities expect quality-related data to be complete, accurate and traceable at all times.

Typical findings relate to inadequate access rights, missing audit trails or deficiencies in electronic records.
At the same time, inspectors check whether risks are systematically assessed and appropriate control measures defined.

A structured risk management approach helps companies to identify potential vulnerabilities at an early stage and to comply with regulatory requirements on a long-term basis. This enables many of the typical GMP non-conformities to be avoided in advance.

International GMP inspections also require precise and unambiguous communication. Professional pharmaceutical translations ensure the correct transmission of quality-related information and documents. During audits and inspections, experienced pharmaceutical interpreters ensure that technical content is conveyed clearly and that misunderstandings are avoided.

Image: Markus Spiske, unsplash.com